EFFECT OF 5-AZACYTIDINE ON DIFFERENTIATION AND DNA METHYLATION IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL-60)

Authors:
  • JCJK CHRISTMAN
    JK CHRISTMAN
  • NMN MENDELSOHN
    N MENDELSOHN
  • DHD HERZOG
    D HERZOG
  • NSN SCHNEIDERMAN
    N SCHNEIDERMAN

  • 1 January 1983
    • journal article
    • research article
    • Vol. 43  (2) , 763-769
    • PMID:6184156
Abstract
One of the most rapidly quantitated indices of myeloid maturation in HL-60 cells is their ability to respond to the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate with increased respiratory burst activity. HL-60 cells exposed to the antileukemic drug, 5-azacytidine (3-5 .mu.M) for 24 h and subsequently cultured in its absence for 2-3 days develop an enhanced ability to respond to 12-O-tetradecanoylphorbol-13-acetate with increased respiratory burst activity detectable as an increase both in hexose monophosphate shunt activity and in the proportion of the population producing superoxide anion. 5-Azacytidine treatment also causes marked inhibition of DNA methyltransferase, and thus DNA synthesized by HL-60 cells during the 24-h period of analog treatment is essentially devoid of methylated cytosine residues. Apparently, a general inhibitor of transmethylation reactions, L-ethionine, can induce differentiation of HL-60 cells, that changes in gene expression triggered by these compounds may be linked to their ability to alter patterns of DNA methylation. Since at least 50% of HL-60 cells capable of forming colonies in soft agar after a 24-h exposure to 5-azacytidine yield progeny that mature (i.e., produce superoxide anion in response to 12-O-tetradecanoylphorbol-13-acetate) 2 wk after 5-azacytidine treatment, the results also indicate that the changes induced in HL-60 cells by limited exposure to 5-azacytidine are heritable and can influence gene expression many generations after treatment has been terminated.